Back to top
more

Celgene Corporation (CELG)

(Delayed Data from NSDQ)

$96.88 USD

96.88
5,654,306

+1.67 (1.75%)

Updated May 3, 2019 04:00 PM ET

After-Market: $96.84 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks News

Valeant (VRX) Tops Q4 Earnings, Shares Down on Tepid View

Valeant's (VRX) fourth-quarter results beat expectations but the guidance of 2017 was disappointing.

    Jazz Pharma (JAZZ) Q4 Earnings Beat, Sales Miss Estimates

    Jazz Pharmaceuticals Public Limited Company (JAZZ) reported fourth-quarter 2016 earnings of $1.91 per share which beat the Zacks Consensus Estimate of $1.65.

      Kite Pharma (KITE) Posts Q4 Loss; Up on Positive Cancer Data

      Kite Pharma, Inc. (KITE) reported narrower-than-expected loss in the fourth quarter of 2016.

        Medicines Company (MDCO) Q4 Loss Narrower than Expected

        The Medicines (MDCO) reported a loss of $1.29 per share (including the impact of share-based compensation expenses) in the fourth quarter of 2016, narrower than Zacks Consensus Estimate of a loss of $1.43.

          Why Is Celgene (CELG) Up 6% Since the Last Earnings Report?

          Celgene (CELG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

            Arpita Dutt headshot

            Biotech Stock Roundup: Kite Soars on CAR-T Data, EXEL in Immuno-Oncology Deals

            Key updates this week include earnings results from companies like BioMarin and positive data on Kite's (KITE) lead pipeline candidate.

              Arpita Dutt headshot

              M&As, Pipeline Catalysts to Drive Pharma Sector

              The sector's fundamentals remain strong -- innovation, mergers and acquisitions (M&As), product approvals and positive data flow should act as catalysts.

                Endo (ENDP) Beats on Q4 Earnings, Revenues; Guides Low

                Endo's (ENDP) Q4 results beat expectations but the outlook for 2017 was disappointing and lagged expectations

                  Horizon (HZNP) Misses on Earnings in Q4, View Disappoints

                  Horizon Pharma's (HZNP) fourth quarter results were disappointing with the company missing on both top- and bottom line estimates. Moreover, the guidance for 2017 also fell short of expectations.

                    Theravance (TBPH) Q4 Loss Wider than Expected, Revenues Beat

                    Theravance Biopharma, Inc. (TBPH) reported fourth-quarter 2016 loss of $1.36 per share, much wider than both the Zacks Consensus Estimate of a loss of $1.07 and the year-ago loss of $1.23.

                      Perrigo to Sell Tysabri Royalties; Issues Tepid 2017 View

                      The company also announced that it has signed an agreement to divest the royalties it receives in multiple sclerosis drug, Tysabri, in order to monetize the asset.

                        Achillion (ACHN) Reports Narrower-Than-Expected Q4 Loss

                        Shares of Achillion Pharmaceuticals, Inc. (ACHN) lost almost 9% on Feb 24, 2017, in spite of the company reporting narrower-than-expected fourth-quarter loss a day before.

                          Intercept (ICPT) Q4 Loss Wider than Expected, Revenues Beat

                          Intercept Pharmaceuticals, Inc. (ICPT) posted a loss of $4.84 per share in the fourth quarter of 2016, wider than the Zacks Consensus Estimate of a loss of $3.58.

                            Emergent (EBS) Beats Earnings, Revenue Estimates in Q4

                            Emergent BioSolutions, Inc. (EBS) reported earnings of 74 cents per share in the fourth quarter of 2016, which surpassed the Zacks Consensus Estimate of 60 cents. However, the reported figure decreased from 77 cents earned in the year-ago period.

                              BioMarin (BMRN) Q4 Loss Narrower than Expected; Sales Beat

                              BioMarin Pharmaceutical Inc. (BMRN) reported a loss of 37 cents per share in the fourth quarter of 2016.

                                Juno Therapeutics (JUNO) Q4 Earnings: What's in the Cards?

                                Juno Therapeutics Inc. (JUNO) is set to report fourth-quarter 2016 results on Mar 1, after the market closes.

                                  Arpita Dutt headshot

                                  Forget Alexion, Buy these 4 Biotech Stocks Instead

                                  We advise investors to consider biotech stocks which sport a strong Zacks Rank and have interesting pipelines/products and growth potential.

                                    Agios Pharma (AGIO) Q4 Loss Narrower than Expected; Stock Up

                                    Agios Pharmaceuticals, Inc. (AGIO) posted fourth-quarter 2016 loss of $1.34 per share, narrower than the Zacks Consensus Estimate of a loss of $1.55 but wider than the year-ago loss of $1.08.

                                      Amgen Looking to Broaden Leukemia Drug Blincyto's Label

                                      Biotech major Amgen Inc. (AMGN) announced that it has submitted a supplemental biologics license application (sBLA) to the FDA for its leukemia immunotherapy Blincyto.

                                        Arpita Dutt headshot

                                        Biotech Stock Roundup: Regeneron's Praluent to Remain on Market for Now, GILD Presents HIV Data

                                        Gilead (GILD) presented promising HIV data while Regeneron's PCSK9 inhibitor will remain on the market during the appeals process.

                                          The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics

                                          The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics

                                            Arpita Dutt headshot

                                            Forget Gilead, Buy These 5 Biotech Stocks Instead

                                            With Gilead (GILD) providing a not-so-rosy outlook for 2017 as its HCV franchise continues to face challenges, here's a look at 5 biotech stocks that look better-positioned.

                                              The Zacks Analyst Blog Highlights: Celgene, Cellectis S.A., Exelixis, Exact Sciences and Sunesis Pharmaceuticals

                                              The Zacks Analyst Blog Highlights: Celgene, Cellectis S.A., Exelixis, Exact Sciences and Sunesis Pharmaceuticals

                                                The Zacks Analyst Blog Highlights: Celgene, Exelixis, Ligand Pharmaceuticals and RedHill Biopharma

                                                The Zacks Analyst Blog Highlights: Celgene, Exelixis, Ligand Pharmaceuticals and RedHill Biopharma

                                                  Swarup Gupta headshot

                                                  5 Great Biotech Stocks to Buy Now

                                                  Biotechs have stabilized and still offer the potential to deliver substantial returns.